ProShare Advisors’s Ultragenyx Pharmaceutical RARE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $531K | Buy |
+15,889
| New | +$395K | ﹤0.01% | 1053 |
|
|
2024
Q4 | – | Sell |
-5,885
| Closed | -$327K | – | 2291 |
|
|
2024
Q3 | $327K | Sell |
5,885
-5,257
| -47% | -$268K | ﹤0.01% | 1409 |
|
|
2024
Q2 | $458K | Buy |
11,142
+5,068
| +83% | +$216K | ﹤0.01% | 1031 |
|
|
2024
Q1 | $284K | Buy |
6,074
+486
| +9% | +$22.9K | ﹤0.01% | 1458 |
|
|
2023
Q4 | $267K | Buy |
+5,588
| New | +$217K | ﹤0.01% | 1463 |
|
|
2023
Q3 | – | Sell |
-4,762
| Closed | -$220K | – | 1858 |
|
|
2023
Q2 | $220K | Sell |
4,762
-677
| -12% | -$31.4K | ﹤0.01% | 1478 |
|
|
2023
Q1 | $218K | Sell |
5,439
-1,423
| -21% | -$61.1K | ﹤0.01% | 1401 |
|
|
2022
Q4 | $318K | Sell |
6,862
-145
| -2% | -$5.7K | ﹤0.01% | 1202 |
|
|
2022
Q3 | $290K | Buy |
7,007
+414
| +6% | +$21.3K | ﹤0.01% | 1174 |
|
|
2022
Q2 | $393K | Sell |
6,593
-2,146
| -25% | -$132K | ﹤0.01% | 1056 |
|
|
2022
Q1 | $634K | Sell |
8,739
-2,572
| -23% | -$179K | ﹤0.01% | 1138 |
|
|
2021
Q4 | $951K | Sell |
11,311
-4,787
| -30% | -$390K | ﹤0.01% | 1050 |
|
|
2021
Q3 | $1.45M | Buy |
16,098
+1,680
| +12% | +$152K | ﹤0.01% | 796 |
|
|
2021
Q2 | $1.38M | Sell |
14,418
-13,010
| -47% | -$1.36M | ﹤0.01% | 862 |
|
|
2021
Q1 | $3.12M | Buy |
27,428
+2,275
| +9% | +$310K | 0.01% | 570 |
|
|
2020
Q4 | $3.48M | Buy |
25,153
+7,353
| +41% | +$872K | 0.01% | 505 |
|
|
2020
Q3 | $1.46M | Sell |
17,800
-364
| -2% | -$30.2K | 0.01% | 638 |
|
|
2020
Q2 | $1.42M | Buy |
18,164
+6,028
| +50% | +$399K | 0.01% | 625 |
|
|
2020
Q1 | $539K | Sell |
12,136
-9,063
| -43% | -$471K | ﹤0.01% | 718 |
|
|
2019
Q4 | $905K | Sell |
21,199
-1,918
| -8% | -$79.1K | ﹤0.01% | 831 |
|
|
2019
Q3 | $989K | Sell |
23,117
-548
| -2% | -$29.8K | 0.01% | 747 |
|
|
2019
Q2 | $1.5M | Sell |
23,665
-3,326
| -12% | -$212K | 0.01% | 647 |
|
|
2019
Q1 | $1.87M | Buy |
26,991
+3,427
| +15% | +$196K | 0.01% | 614 |
|
|
2018
Q4 | $1.02M | Sell |
23,564
-4,318
| -15% | -$236K | 0.01% | 699 |
|
|
2018
Q3 | $2.13M | Sell |
27,882
-327
| -1% | -$26.6K | 0.01% | 589 |
|
|
2018
Q2 | $2.17M | Sell |
28,209
-1,604
| -5% | -$104K | 0.01% | 608 |
|
|
2018
Q1 | $1.52M | Sell |
29,813
-74
| -0.2% | -$3.73K | 0.01% | 682 |
|
|
2017
Q4 | $1.39M | Buy |
29,887
+2,312
| +8% | +$113K | 0.01% | 724 |
|
|
2017
Q3 | $1.47M | Buy |
27,575
+1,540
| +6% | +$91.2K | 0.01% | 630 |
|
|
2017
Q2 | $1.62M | Sell |
26,035
-1,487
| -5% | -$89.6K | 0.02% | 606 |
|
|
2017
Q1 | $1.86M | Sell |
27,522
-5,797
| -17% | -$442K | 0.02% | 571 |
|
|
2016
Q4 | $2.34M | Buy |
33,319
+3,839
| +13% | +$272K | 0.03% | 503 |
|
|
2016
Q3 | $2.09M | Sell |
29,480
-5,151
| -15% | -$329K | 0.03% | 476 |
|
|
2016
Q2 | $1.69M | Buy |
34,631
+305
| +0.9% | +$19.7K | 0.02% | 572 |
|
|
2016
Q1 | $2.17M | Sell |
34,326
-3,825
| -10% | -$250K | 0.03% | 429 |
|
|
2015
Q4 | $4.28M | Buy |
38,151
+3,719
| +11% | +$372K | 0.05% | 318 |
|
|
2015
Q3 | $3.32M | Buy |
34,432
+1,215
| +4% | +$139K | 0.05% | 341 |
|
|
2015
Q2 | $3.4M | Buy |
33,217
+3,580
| +12% | +$278K | 0.05% | 362 |
|
|
2015
Q1 | $1.84M | Buy |
29,637
+7,004
| +31% | +$389K | 0.02% | 587 |
|
|
2014
Q4 | $993K | Buy |
+22,633
| New | +$1.04M | 0.01% | 861 |
|
Other funds holding RARE
RI
FCM
ProShare Advisors's RARE Position: Q2 2026 in Review
ProShare Advisors opened a new position in Ultragenyx Pharmaceutical (RARE) in Q2 2026: 15,889 shares worth $531K. The stake represents ﹤0.01% of the portfolio and ranks #1053 among its holdings. This is a return to the name: ProShare Advisors previously reported a position in RARE as recently as Q3 2024.
ProShare Advisors first reported a position in RARE in Q4 2014 and has held it in 40 quarters since. The position peaked at $4.28M in Q4 2015. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.
- ProShare Advisors held 15,889 shares of Ultragenyx Pharmaceutical worth $531K as of Q2 2026.
- Ultragenyx Pharmaceutical was a new ProShare Advisors position in Q2 2026.
- Ultragenyx Pharmaceutical made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #1053 holding.
- ProShare Advisors first reported a position in Ultragenyx Pharmaceutical in Q4 2014 and has held it in 40 quarters since.
- ProShare Advisors's Ultragenyx Pharmaceutical position peaked at $4.28M in Q4 2015.
- 311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.
Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.